Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron

By December 2021, about 80% of people over the age of 12 had been vaccinated in Japan, and almost all people were vaccinated with the mRNA vaccine. We investigated here the anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. A total of 32 SARS-CoV2 omicron...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Eisuke, Nagai, Etsuko, Saito, Makoto, Isobe, Masamichi, Konuma, Takaaki, Koga, Michiko, Tsutsumi, Takeya, Nannya, Yasuhito, Yotsuyanagi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971116/
https://www.ncbi.nlm.nih.gov/pubmed/35397976
http://dx.doi.org/10.1016/j.jiac.2022.03.021
Descripción
Sumario:By December 2021, about 80% of people over the age of 12 had been vaccinated in Japan, and almost all people were vaccinated with the mRNA vaccine. We investigated here the anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. A total of 32 SARS-CoV2 omicron breakthrough infection was included in the study. The median antibody titer at breakthrough infection was 776 AU/mL overall, of which the median antibody titer of BNT162b2 vaccinated was 633 AU/mL and that of mRNA-1273 vaccinated was 9416 AU/mL. This result suggests that low levels of antibody titers 6 months after vaccination do not provide sufficient antibodies to prevent the omicron variant breakthrough infection, which may occur with a higher anti-spike antibody titer after vaccination with mRNA-1273. However, antibody titers in some patients were comparable to those immediately after the second vaccination with either mRNA vaccine.

Ejemplares similares